Relationship of Anifrolumab Pharmacokinetics With Efficacy and Safety in Patients With Systemic Lupus Erythematosus.

Yen Lin ChiaJianchun ZhangRaj TummalaTomas RouseRichard A FurieEric F Morand

Published in: Rheumatology (Oxford, England) (2021)

While higher Cave predicted greater efficacy, consistent positive benefit favouring anifrolumab 300 mg vs placebo was observed in BICLA and SRI(4) responses across Cave subgroups in the TULIP trials. There was no evidence of exposure-driven safety events.

Keyphrases

double blind
phase iii
study protocol
open label